Home › Funds › Lynx1 Capital Management LP › IKT

Lynx1 Capital Management LP position in IKT

INHIBIKASE THERAPEUTICS INC · Health Care

Lynx1 Capital Management LP reported holding 20,000 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1K, representing 0.00% of its reported portfolio and ranking #31 among its reported holdings. Lynx1 Capital Management LP has disclosed IKT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)20.00K sh
Reported value held$1.20K
Portfolio Weight0.00%
First reportedQ2 2026
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Lynx1 Capital Management LP's IKT position evolved

Lynx1 Capital Management LP first disclosed a stake in IKT in Q2 2026 at 20,000 shares (US$41K). Across 2 filings, Lynx1 Capital Management LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 20,000 shares valued at US$1K.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 20.00K $40.60K New
Q3 2026 20.00K $1.20K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IKT and 13F data

IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 63 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.8M), Soleus Capital Management, L.P. (US$23.1M), Trails Edge Capital Partners, LP (US$18.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IKT

All IKT fund holders →

FAQ

How long has Lynx1 Capital Management LP held IKT?

Lynx1 Capital Management LP has disclosed IKT holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Lynx1 Capital Management LP's current position in IKT?

As of Q3 2026, Lynx1 Capital Management LP holds 20.00K shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $1.20K, representing 0.00% of its reported portfolio and ranking #31.

Has Lynx1 Capital Management LP been buying or selling IKT?

In the latest 13F filing (Q3 2026), Lynx1 Capital Management LP held unchanged its position in IKT.

Which other funds hold IKT?

Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, among 63 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.